Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras
Patients To Start Receiving The Drug In The Next Few Weeks
Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.
You may also be interested in...
A landmark population-level agreement between Novartis and the National Health Service for the gene silencing therapy Leqvio is now being implemented following the thumbs up from health technology assessment body NICE.
Keeping Track: US FDA Approves Amgen’s Lumakras, Myovant’s Myfembree; New Claims For Biohaven’s Nurtec, BMS’ Zeposia
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.